Feb 3, 2016, 10:42 AM

Fertility possible during anticancer drugs consumption

Fertility possible during anticancer drugs consumption

TEHRAN, Feb. 03 (MNA) – Iranian researchers studied the effect of a type of nanoparticle on protection of reproduction and fertility system in cancer-suffering animal samples, INIC reports.

According to Iran Nanotechnology Initiative Council (INIC), Iranian researchers studied the effect of a type of nanoparticle on protection of reproduction and fertility system in cancer-suffering animal samples.

The study proved the effectiveness of nanoparticles in decreasing the side effects of anticancer drugs on the sexual hormones of female rats.

Doxorubicin is one of the anticancer drugs, which is widely used in the treatment of various types of aggressive tumors. The side effects appear a week after the injection. The side effects include nausea, vomiting and temporary reduction in the number of white and red blood cells and plackets. In addition, doxorubicin has severe toxicity effect on reproduction system and disables the fertility of patients.

This research studies the protective effect of selenium and zinc oxide nanoparticles on reproduction system, fertility, tissue changes in uterus and ovary of mature female rats after treatment with doxorubicin.

Results proved the effective performance of selenium and zinc oxide nanoparticles in reducing side effects of doxorubicin and the protecting the reproduction system in rats.

Formation of free radicals, including reactive oxygen species (ROS), is one of the known mechanisms of doxorubicin. Free radicals harm proteins and fats inside the cells, and they break the cell and the damaged tissue.

The use of zinc oxide and selenium nanoparticles reduces side effects of doxorubicin on antioxidant properties and reproduction indicators such as sexual hormones, and improves them.

Results of the research have been published in Nanoscale Research Letters, vol. 7, issue 1, 2015, pp. 187-191.

 

MS/PR

 

News ID 114127

Tags

Your Comment

You are replying to: .
  • captcha